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The binding site for an inhibitor of squalene:hopene cyclase 
determined using photoaffinity labeling and molecular modeling 
Tongyun Dang, Ikuro Abe*, Yi Feng Zheng and Glenn D Prestwich 
Background: The squalene:hopene cyclases (SHCs) are bacterial enzymes 
that convert squalene into hopanoids, a function analogous t  the action of 
oxidosqualene cyclases (OSCs) in eukaryotic steroid and triterpenoid 
biosynthesis. We have identified the binding site for a selective, potent, 
photoactivatable inhibitor of an SHC. 
Results: SHC from Aficyclobacillus acidocaldarius was specifically labeled 
by [3H]Ro48-8071, a benzophenone-containing hypocholesteremic drug. 
Edman degradation of a peptide fragment of covalently modified SHC 
confirmed that Ala44 was specifically modified. Molecular modeling, using 
X-ray-derived protein coordinates and a single point constraint for the 
inhibitor, suggested several geometries by which Ro48-8071 could occupy 
the active site. 
Conclusions: A covalent complex of a potent inhibitor with a squalene cyclase 
has been characterized. The amino acid modification and molecular modeling 
suggest that Ro48-8071 binds at the junction between the central cavity and 
substrate entry channel, therefore inhibiting access of the substrate to the 
active site. 
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Introduction 
Oxidosqualene cyclases (OSCs) and squalene:hopene 
cyclases (SHCs) [EC 5.4.99.7] are pivotal enzymes in 
triterpenoid biosynthesis [1]. OSCs cyclize 2,3-oxidosqua- 
lene (OS) into lanosterol in fungi and mammals, and into 
cycloartenol and a variety of pentacyclic triterpenes in 
plants. Lanosterol and cycloartenol are then transformed 
into a medley of steroids that serve numerous roles, includ- 
ing stabilizing lipid bilayers by regulating membrane flu- 
idity, functioning as hormones or feedback regulators of 
cholesterol homeostasis, and acting as meiosis-activating 
factors [2,3]. Hypercholesterolemia is major risk factor for 
the development of atherosclerotic vascular diseases, and 
modulation of serum cholesterol with hypocholesteremic 
drugs has been shown to decrease the risk of cardiovascular 
disease [4]. Statins, a family of HMG-CoA reductase 
inhibitors that are currently used as cholesterol-lowering 
drugs, could, in principle, suppress all post-mevalonate 
biosynthetic pathways [4]. A preferred approach would be 
selective inhibition of OSC, as this would uniquely sup- 
press the committed step in sterol biosynthesis. 
In prokaryotes, qualene is converted by SHCs into penta- 
cyclic triterpenoids (Figure 1), which have several func- 
tions analogous to those of eukaryotic steroids [5]. The first 
cloned and overexpressed SHC was obtained from 
the thermoacidophile Alicyclobacillus acidocaldarius [6].
Subsequently, SHC genes in Zymomonas mobilis [7], Methy- 
lococcus capsulatus [81 and Bradyrhizobiumjaponicum [9] have 
been cloned and expressed, and conserved hopanoid modi- 
fication genes were cloned from an shc operon in Z. mobilis 
and B.japonicum [10]. The SHC genes from these species 
share 48-70% identity among their predicted protein 
sequences. Although no SHCs (or OSCs) from human 
pathogens have yet been cloned, it is conceivable that SHC 
or OSC inhibitors may provide leads for new antibiotics. 
A comparison of eukaryotic OSCs and prokaryotic SHCs 
reveals a 17-38% sequence homology between these 
classes of enzymes. Both cyclase classes have a highly con- 
served repeating motif rich in glutamine and tryptophan 
residues (the QW repeat) [11,12], and an acidic-rich 
domain [13] that has been implicated in catalysis [14,15]. It 
is now believed that cyclization proceeds through a series 
of discrete conformationally rigid, partially cyclized carbo- 
cationic intermediates, either via a 'chair-boat-chair' or
'chair-chair-chair' conformation for OS, or via the all pre- 
chair conformation for squalene (Figure 1) [1,16]. Compu- 
tational studies support the near-concerted manner of the 
formation of the A ring with electrophilic epoxide opening 
[17,18], and recent experimental evidence suggests the 
occurrence ofa Markovnikov-like formation of a five-mem- 
bered C-ring followed by rearrangement to the six-mem- 
bered C-ring prior to completion of the tetracyclization by
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(a) The proposed mechanism for the cyclization of squalene (1) to hop-22-ene (3) and hopan-22-ol (4) by SHC. The ratio of 3:4 can vary from 4:1 
to 16:1 under various enzymatic cyclization conditions. (b) The structure of the photoactivatable inhibitor Ro48-8071 (5). 
OSC [19-21]. Similarly, pentacyclization by SHC appears 
to proceed through a five-membered ring intermediate en 
route to the hopanoid six-membered D-ring [22]. Follow- 
ing polycyclization, rearrangement and deprotonation of 
the protosteryl C-20 cation (for OS as substrate) or deproto- 
nation of the C-22 cation (for squalene as substrate) yields 
cyclization products. The specific labeling of the carboxy- 
late form of Asp456 in rat OSC by [3H](3S)-29-methyli- 
dene-2,3-oxidosqualene (29-MOS), a mechanism-based 
irreversible inhibitor, implicated an essential function for 
Asp456 in stabilization of the C-20 carbocation [23]. Site- 
directed mutagenesis of Asp376 and Asp377 of SHC, the 
residues homologous to Asp456 and Cys457 of rat OSC, 
showed that both are crucial for catalysis [14]. 
We have reported previously [24] the efficient and spe- 
cific labeling of both rat OSC and SHC by [3H]Ro48-8071 
(5b; Figure 1), a photoactivatable b nzophenone (BP)- 
containing compound eveloped at Hoffmann-La Roche 
as an orally bioavailable pharmaceutical agent for lowering 
serum cholesterol levels [25]. We report here the identifi- 
cation of the amino acid residue of SHC that is photocova- 
lently modified by Ro48-8071. On the basis of this result 
and the published crystal structure of SHC complexed to 
an amine N-oxide detergent molecule [26], two alterna- 
tive binding conformations of the inhibitor in the catalytic 
cavity were predicted by molecular modeling. These 
results led us to propose a mode of action for the inhibitor 
that is consistent with its location in the entrance channel 
of the catalytic site. 
Resu l ts  
Recombinant SHC was expressed and purified as 
described previously [6,24]. In order to have a sufficient 
mass of labeled peptide fragments for sequence analysis, 
photoaffinity labeling was conducted in two stages. 
Homogeneous SHC was first photoaffinity labeled 
(45 min, 4°C, 360 nm) with [3H] Ro48-8071 (5b) at an 
inhibitor concentration equivalent o 50% of its IC50 
value. This accomplished efficient modification, generally 
>90% incorporation of radiolabel, with the high-specific- 
activity radioligand. A second labeling under the same 
conditions was then conducted with a threefold molar 
excess (3 ~tM) of unlabeled Ro48-8071 (5a) relative to the 
SHC concentration. As reported previously, we observed 
that [3HI Ro48-8071 specifically labeled the SHC leading 
to a single radiolabeled band on a fluorogram of proteins 
separated using sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) [24]. 
An aliquot (20 Ixg) of [3H]Ro48-8701-1abeled SHC was 
then digested with CNBr in formic acid. After the CNBr 
digestion, a tritium-labeled peptide fragment appeared 
as a unique 3 kDa band on SDS-PAGE and in the corre- 
sponding fluorogram (data not shown). Electrophoretic 
transfer from the gel to PVDF membrane was unsuc- 
cessful, probably due to the hydrophobicity and size of 
the modified peptide. Separation of products was 
instead achieved by reverse-phase high-performance 
liquid chromatography (RP-HPLC),  giving three 
radioactive fractions at 36, 40 and 44 min. To determine 
which fraction(s) contained the covalently modified 
peptide(s), either [3H] Ro48-8071 alone or [3H] 
Ro48-8071-1abeled SHC prior to digestion was analyzed 
under the same HPLC conditions; radioactivity was 
observed in fraction 40 for the former and fraction 44 for 
the latter. Fraction 36 was therefore suspected to contain 
the labeled peptide. 
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Improved resolution was required prior to sequence analy- 
sis. Fractions 35 and 36 were therefore pooled and again 
subjected to RP-HPLC. Fraction 3501 (collection time of 
35.01-35.25 min) showed the highest radioactivity, 
whereas fraction 3526 (35.26 min-35.50 min) showed 50% 
lower radioactivity. Edman degradation of fraction 3501 
revealed two overlapping sequences, which could be 
deconvolved to a primary sequence beginning with 
EKIRR (using single-letter amino-acid code) and a sec- 
ondary sequence beginning with EAEYVV. The primary 
sequence (EKIRR...) corresponded to an anticipated 42- 
residue CNBr fragment peptide with a calculated mass of 
4880.2 Da starting with Glu62 (cleavage at Met61). The 
secondary sequence (EAEYV...) corresponded to a 19- 
residue peptide starting with Glu43 (cleavage at Met42) 
with a calculated mass of 2346.6 Da (without ligand). 
Edman degradation of fraction 3476 (34.76-35.00 rain) 
also showed the primary sequence EKIRR .... although 
this fraction lacked radioactivity, suggesting that this 
primary sequence was not from the [3H]Ro48-8071- 
labeled peptide. Similarly, Edman analysis of the lower 
radioactivity fraction 3526 confirmed the presence of the 
EAEYVV... sequence, establishing that the peptide start- 
ing with Glu43 is indeed the labeled CNBr fragment of 
SHC. The eluted phenylthiohydantoin (PTH) amino acid 
derivatives obtained during the Edman degradation of 
fraction 3501 were monitored by liquid scintillation count- 
ing (LSC; Figure 2); only the second cycle showed signifi- 
cant radioactivity during the 30 cycles of Edman 
sequencing. On the basis of these results, we concluded 
that Ala44 was the specifically labeled amino acid residue. 
To examine further the location and orientation of the 
noncompetitive inhibitor Ro48-8071 in the SHC active 
site, we used molecular modeling in conjunction with the 
X-ray structure coordinates for the published three-dimen- 
sional structure of SHC [26]. The modeling methods 
follow standard protocols [27,28], and include minimiza- 
tion of the protein structure prior to docking to accommo- 
date hydrogen atoms not included in the crystal structure 
coordinates [29]. After generating a solvent-accessible 
surface on SHC using the Connolly algorithm [30] with 
HzO molecules (radius = 1.4 ~_), Ro48-8071 was manually 
docked into SHC with the BP  carbonyl oxygen con- 
strained to be within 3.0-5.0 A of Ala44, while monitoring 
docking energy to achieve a minimum value. This con- 
straint was imposed as a result of the photoaffinity-labeling 
experiment, which fixes the distance between the BP car- 
bonyl and abstracted C-H bond to be within 3.1 ,~ [31]. 
Two positions of Ro48-8071 were found to have the 
lowest docking energy. In one position, the tertiary amine 
of Ro48-8071 points towards Trp489 (Figure 3a; orienta- 
tion I); in the other position, the tertiary amine points 
towards Trp169 (Figure 3b; orientation II). The docked 
structures were first subjected to energy minimization and 
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(a) Amino acid sequencing and (b) radioassay for fraction 3501 of 
[3H]Ro48-8071-labeled SHC peptide after CNBr digestion. 
then to dynamic simulations as described in the Materials 
and methods section. During energy minimization, the 
nonbonded repulsion energy was greatly decreased, pre- 
sumably as a result of allowing the initially rigid conforma- 
tion of the ligand to avoid direct clashes with amino acid 
residues in the active site. The BP oxygen was predicted 
to be close to the Glu45 carboxylate group, particularly in 
the average structure of the dynamics imulation for orien- 
tation II (Figure 3b), thus suggesting that Giu45 could be 
implicated in stabilization of a cationic cyclization i ter- 
mediate. The labeling of Ala44 by the BP moiety of 
Ro48-8071 echoes this expected orientation; the known 
propensity of the BP diradicaloid species to abstract 
hydrogen from C-H bonds, particularly methyl or Co~ 
hydrogens, would rationalize the labeling of Ala44 rather 
than Glu45 [31]. 
Figure 4a illustrates the calculated solvent-accessible 
surface of the SHC active-site cavity unoccupied by an 
inhibitor molecule. Figure 4b shows a view of the energy- 
minimized structure of orientation I of Ro48-8071 in this 
solvent-accessible cavity. Two hydrogen bonds between 
the protein and the inhibitor were predicted for this orien- 
tation. The overall root mean square deviation (rmsd) for 
backbone atoms between the minimized structure and 
crystal structure was 1.46 A. One hydrogen bond was pre- 
dicted between the BP carbonyl oxygen and Glu45 amide 
hydrogen (3.16~.), whereas the other was between the 
Ro48-8071 aryl f uorine atom and the Gin262 amide 
hydrogen (3.07 A). No hydrogen bonds for the flexible 
amine end of Ro48-8071 were predicted, although the 
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Stereopairs illustrating predicted average 
structures for dynamics simulations for two 
minimum-energy orientations of the 
Ro48-8071-SHO complex. (a) Orientation I. 
No hydrogen bonds were predicted. Several 
residues (e.g. Vail 74, Asp376 and Asp377) 
do not appear to be involved in the positioning 
of the Ro48-8071 inhibitor, but are shown as 
an aid in orienting the molecule for 
comparison with other published structural 
data [26,44]. (b) Orientation II. A hydrogen 
bond is predicted between the BP oxygen 
and the Glu45 amide hydrogen. The tertiary 
amine of Ro48-8071 might be stabilized by 
interactions with amide carbonyl groups of 
Ile261 and Trp169. 
protonated tertiary amine might be stabilized by Tyr420 
(3.75 A). No hydrogen bonds were predicted for the 
average structure following the dynamics simulation 
(Figure 3a). 
The energy-minimized structure for orientation II 
(Figure 4c) predicted that the BP carbonyl oxygen would 
move closer to Glu45 and Ala44, especially in the average 
structure of dynamics imulations (Table 1). The rmsd for 
backbone atoms between the minimized and crystal struc- 
tures was 1.48 ~- for this orientation; this value is essen- 
tially identical to the value for orientation I. The BP 
oxygen was closer to A44CB than to A44CA, suggesting 
the possibility that the methyl group (C[~) instead of the 
Ca of Ala44 might be the site of covalent modification. No 
hydrogen bonds were predicted between the BP group 
and SHC. The protonated tertiary amine hydrogen was 
predicted, however, to form a hydrogen bond with the 
Thr173 hydroxyl group (distance of 2.93 A). In addition, 
the protonated tertiary amine might also be stabilized by 
the Trp169 backbone carbonyl group (3.41 ~.). In the 
average structure obtained from the dynamics imulation, 
a hydrogen bond was predicted between the BP carbon yl 
oxygen and the Glu45 backbone amide hydrogen (3.05 A; 
see Figure 3b). Although the hydrogen bond between 
Thr173 and tertiary amine of Ro48-8071 was absent, the 
protonated amine still appeared to interact with amide car- 
bonyl groups from Ile261 and Trp169 (distances of 3.61 
and 3.53 A, respectively; Figure 4b). During the molecular 
dynamics simulation, Ro48-8071 remained at approxi- 
mately the same location as that determined in the 
energy-minimized structure, therefore implicating forma- 
tion of a stable complex with SHC. This constant location 
was also observed for orientation I. 
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The active site of SHC. (a) The calculated solvent-accessible surface 
(generated using a water molecule as the probe) is shown in dot 
contour. All aromatic residues lining the active-site cavity are numbered 
and the sidechains are shown. The central cavity is between Asp376 
and Glu45. The postulated channel for squalene entrance is 
represented by Vail 74. Another possible hydrophobic hannel can be 
/ ) i  
4 ¸ 
~'r> ' 
seen near the upper part of the figure as indicated by His451. (b) The 
cavity occupied by a space-filling model of Ro48-80?1 in energy- 
minimized orientation I. (¢) The cavity occupied by a space-filling model 
of Ro48-8071 in energy-minimized orientation II. The red crosses in 
(b) and (c) represent crystallographically defined water molecules. 
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Table 1 
Calculated distances between the R048-8071 BP carbonyl oxygen and selected SHC atoms. 
Orientation I Orientation II 
Starting Minimized Dynamics Starting Minimized Dynamics 
BP--~45CD (/~) 3.48 4.64 4.89 4.67 4.15 3.66 
BP-~A44CA (/~) 3.91 4.39 4.79 2.78 4.53 3.79 
BP--)A44CB (A) 4.62 4.86 4.57 3.62 3.82 3.77 
BP-~N + (A) 14.74 14.08 14.05 14.74 13.95 13.41 
Distance of the structure before (starting) and after (minimized) the energy minimization, as well as the average structure of dynamics simulation 
(dynamics) are shown. 
For both orientations I and 1I, Ro48-8071 adoPoted a semi- 
extended structure with a length of about 14 A (Table 1). 
This compares well with the lenogth of the pentacyclic 
intermediate (C-3 to C-22, 12.29A; Figure 1). Although 
the BP group was maintained close to Ala44 and Glu45 in 
both predicted orientations, the inhibitor locations differ 
considerably in the predicted position of the amino-termi- 
nal end, with the tertiary amine near Trp489 (Figure 3a) 
and Trp169 (Figure 3b). The primary constraint that was 
applied arose from the requirement that the hydrogen 
atom abstracted by the excited BP carbonyl oxygen rad- 
icaloid must be within 3.1 A for any bimolecular chemistry 
to occur between the inhibitor and the protein [31]. The 
modeling appears to provide two principal solutions that 
are consistent with this requirement and with molecular 
considerations in the active site. 
Discuss ion  
The cyclization of OS by OSC, and by analogy the cycliza- 
tion of squalene by SHC, is now believed to occur via a 
multistep rocess involving successive carbocationic inter- 
mediates [1,13,16,32]. Until recently, few details of 
protein structure were available that would lend credence 
to the hypothesized mechanisms [14,20,23,33]. It was pro- 
posed that an electrophilic residue would initiate the 
cyclization by protonating the terminal isopropylidene of 
squalene, or by opening the epoxide ring of OS. The iden- 
tity of this residue was postulated to be Asp376 of SHC 
based on the three-dimensional structure with the deter- 
gent N,N-dimethyldodecylamine N-oxide (LDAO) [26] 
bound in the active site, and Asp456 for OSC based on 
mutagenesis and active-site modification studies [15]. 
To date, however, neither OSC nor SHC has been co-crys- 
tallized with a bound substrate- or product-like inhibitor. 
We therefore conducted a photoaffinity-labeling experi- 
ment with a potent inhibitor, Ro48-8071, to determine the 
precise location of the BP photophore in the active site. 
The BP moiety is unique among photoactivatable groups 
in one key regard: photocovalent a tachment only occurs 
when the carbonyl group is constrained to be within 3.1 
of a target C-H bond [31]. No reactive species would be 
produced, as would be the case for carbenes or nitrenes, 
that could diffuse away from the bound site and react non- 
specifically elsewhere with the protein or with solvent [34]. 
The solution of the three-dimensional structures of SHC 
and two sesquiterpene cyclases have led to the postulation 
of two separately evolved families of isoprenoid-cyclizing 
enzymes [35]. The theme of 'template, trigger, chaperone 
and sequester' [36] is maintained in both classes: the sub- 
strate first binds to the enzyme by adopting a specific 
'product-like' conformation; second, the cyclase triggers 
cation formation by metal-assisted diphosphatc dissocia- 
tion (class I) or by protonation of an epoxide or a double 
bond (class II); third, the cyclase chaperones reactive 
carboeationic intermediates through sequential ring-clo- 
sures and rearrangements; and finally, the terpene cyclases 
sequester and stabilize the cationic intermediates, prevent- 
ing solvent access or interception by active-site nucleo- 
philes [35,36]. Both the chaperoning and sequestration can 
now be seen to involve n-cation interactions, first discussed 
for metal cation and carbocation interactions with proteins 
by Dougherty [37], with sidechain aromatic rings. 
The Hoffmann-La Roche team reported a series of BP-con- 
taining compounds as potent, orally active cholesterol-low- 
ering agents that acted as inhibitors of OSC [38]. The 
inhibitory activity was dependent on the distance between 
the nitrogen atom of the tertiary amine and the carbonyl 
group of the BP moiety [25]. Ro48-8071 was indeed a 
potent noncompetitive SHC inhibitor [24], so its mode of 
action was likely to be important in understanding the 
cyclization process. Examination of both possible orienta- 
tions of inhibitor binding (Figures 3 and 4) suggests that 
Ro48-8071 might inhibit SHC by binding at the intersection 
of the squalene ntrance channel and the opening of the 
main central cavity. Two other structurally related classes of 
orally active aromatic, nonterpenoid OSC inhibitors were 
independently discovered at Boehringer Ingelheim Pharma 
KG [39,40]. These noncompetitive inhibitors might act in a 
structurally similar fashion to Ro48-8071, but their activity 
against SHC has not been examined in detail. 
Analysis of a 2.9 A resolution three-dimensional crystal 
structure of SHC showed that the enzyme crystallized as a 
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dimer. The structure revealed two a -a  barrel domains 
that assemble to form a central hydrophobic cavity. These 
a-barrel domains are topologically distinct from the single 
a-helical bundles that characterize the two sesquiterpene 
cyclases [35]. Domain 1 is an c~6-~6 barrel of two concen- 
tric rings of parallel helices, whereas domain 2 appears to 
have evolved from domain 1by gene duplication and loss 
of one of the helices [26]. SHC has a central cavity of 
1200 ~3, in which the catalysis is presumed to take place. 
This cavity is lined with aromatic residues (e.g., Trp312, 
133, 169, 489; Phe365, 605, 437, 129, 166; and Tyr612, 
609, 495, 420); Asp376 and Asp377 are located at the top 
and Glu45 at the bottom of the cavity as illustrated in 
Figure 4. Two of these tryptoph~n residues, Trp169 and 
Trp489, appear to be important in the determination of 
cyclization termination [41]. SHC mutants Trp169-+Phe, 
Trp169---~His and Trp489-->Phe ach furnished a novel 
6/6/6/5 tetracyclic dammarene product in which the 
hopene E ring failed to form and proton loss from the 
dammarenyl C-20 cation led to a 20(21)-methylene group. 
The cavity can accommodate an extended squalene mol- 
ecule, because the distance between the two carboxylate 
groups of Asp376 and Glu45 is 25.11 A (24.85 A in the 
minimized structure); the distance from C-2 and C-22 of 
squalene is 25.22 A. Due to its location and the existence 
of a hydrogen bond between Asp374 and Asp377, 
Asp376 was proposed to protonate the t rminal isopropy- 
lidene bond of squalene [26]. Termination of cyclization 
may occur near Glu45, probably due to steric hindrance. 
A water molecule near the hydrogen-bond network 
involving Gln262:Glu45:Glu93:Arg127 may stabilize or 
quench the C-22 carbocation [26]. Our results suggest 
that Glu45, which is highly conserved in the SHC 
sequences, could be the nucleophilic residue important 
in cyclization termination. As the major product of SHC 
is hopene (3) rather than hopanol (4), Glu45 rather than 
water may act as the stabilizing nucleophile. This role of 
Glu45 is also consistent with the preliminary studies on 
the site of covalent modification of SHC by the suicide 
substrate 29-MOS (T.D., I.A. and Y.F.Z., unpublished 
observations), and by the observation that no products 
were isolated from 29-MOS cyclization that would corre- 
spond to the quenching of cationic intermediate by 
water [42]. It is an unresolved paradox that the alkyla- 
tion of Asp456 of rat OSC by the mechanism-based irre- 
versible inhibitor 29-MOS implicated this residue as the 
putative 'negative point charge' [43] necessary for stabi- 
lization of the C-20 carbocation [23]. The resolution of 
this paradox will entail solving the structure of an SHC 
or OSC structure with either a complexed squalenoid 
substrate mimic or with a covalently attached mecha- 
nism-based inhibitor. In any event, the DCTAEA motif 
containing Asp456 is highly conserved for OSCs [13], 
whether it is involved in initiation or termination of the 
cyclization. For SHC, mutagenesis of either Asp376 or 
Asp377 of the homologous DDTAV motif to nonacidic 
residues resulted in loss of catalytic activity; moreover, 
even the more subtle Asp376---~Glu and Asp377---~Glu 
mutants had only 10% and 0.04% activity, respectively, 
compared with the wild-type enzyme [14]. 
The central cavity can be connected through a nonpolar 
channel to the surface SHC, where a nonpolar plateau of 
1600 ~z was proposed to facilitate diffusion of the sub- 
strate squalene from the membrane [26]. The modeling 
results described here revealed a moderately hydrophobic 
channel close to His451 (Figure 4) not described in the 
original structure [26] but subsequently seen in a higher 
resolution crystal structure that was published uring revi- 
sion of this manuscript [44]. As this channel also has non- 
polar residues on the surface facing outside, it could 
constitute an alternative for substrate ntry, or possibly in 
permitting product release. Although SHC exists as a 
dimer in the presence of 0.3% CsE 4 (n-octyltetraoxyethyl- 
ene) under crystallization conditions, gel filtration shows 
that SHC appears to have a molecular weight of over 
250-300 kDa in the absence of Triton X-100 (T.D. and 
I.A., unpublished observations). This may suggest SHC 
has more than one surface hydrophobic patch. 
S ign i f i cance  
Squalene:hopene cyclase (SHC) is responsible for a tem- 
plated and enzyme-initiated cationic polyolefinic ycliza- 
tion of squalene to hopene. The sequence homology and 
well-conserved regions between SHCs and the eukary- 
otic oxidosqualene cyclases (OSCs) implicate the strongly 
conserved structural and mechanistic similarities. Analy- 
sis of an inhibitor complexed to the three-dimensional 
structure of SHC therefore provides an important insight 
into understanding the enzymatic reaction of OSC. 
This is the first time that a covalently modified SHC 
residue has been identified. Using the site of modification 
as a distance constraint, molecular modeling was 
employed to demonstrate the occupancy of the central 
hydrophobic cavity by a cholesterol-lowering nonter- 
penoid analog. The blocking of the junction of the 
central cavity and the substrate entrance presumably 
accounts for the potency of Ro48-8071 as a noncompeti- 
tive inhibitor of both SHC and OSC. This knowledge 
may help in the design of more potent and selective 
inhibitors of OSC and SHC.  
Mater ia l s  and  methods  
Enzyme preparation and labeling 
SHC from the acidothermophilic bacterium A. acidocaldarius was 
expressed in Escherichia coil and purified as described previously [6]. 
Briefly, membrane proteins were prepared from cell lysate by centrifu- 
gation and then solubilized in the presence of lO/o Triton X-IO0. SHC 
was first separated by heat denaturation of E. coil proteins (60°C for 
10 min); the enriched SHC was then purified by ion exchange on a 
DEAE-Sephacel column. 
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Purified SHC was quantified using the DC Protein Assay kit (Bio-Rad), 
and enzymatic activity was assayed at pH 6.0, 60°C using [14C]-squa- 
lene as the substrate with a reaction buffer containing 100 mM sodium 
citrate and 0.10/0 Triton X-100. [3H]Ro48-8071 was synthesized as 
described previously [24]. SHC was first photoaffinity labeled by 
[3H]Ro48-8071 (a final concentration of 3 nM, 18.7 Ci/mmol), then 
photolabeled with unlabeled Ro48-8071 (threefold molar excess). Both 
photoaffinity-labeling reactions were performed by preincubation at 
60°C in reaction buffer for 15 min, followed by UV irradiation (360 nm) 
for 45 min at 4°0. 
Chemical  and enzymatic cleavage 
[3H]Ro48-8071-Labeled SHC was divided into aliquots of 20 ~g, con- 
centrated and lyophilized using a Speed-vac, and digested overnight 
with CNBr (Sigma, 300-fold molar excess over methionine residues) in 
70% formic acid under argon in darkness. 
Peptide separation and sequencing 
CNBr-digested, [3H]Ro48-8071-1abeled SHC fragments were sepa- 
rated by either ?.5% SDS-PAGE containing Tricine or RP-HPLC. 
SDS-PAGE was performed at constant current (10 mA), followed 
either by fluorography or by transferring to PVDF membrane (Millipore) 
under constant voltage of 50 V for 1 h. The gel was stained with 0.1% 
Coomassie Blue R-250, destained, washed with 100%o acetic acid 
after destaining, impregnated with EN3HANCE (NEN Life Science 
Products), miniaturized with 50O/o polyethylene glycol (PEG, 1450) and 
dried. The dried gel was exposed to X-ray film (Kodak X-Omat AR film) 
for 3-?  days at -80°C. PVDF membranes used for electrotransfer was 
briefly stained with Coomassie Blue R-250 and the radiolabeled frag- 
ment was sequenced by Edman degradation (ABI model 4?7). 
Radioactivity of sequencing eluates were counted by LSC. 
For HPLC separation, a C a RP column (Whatman, 4.6 mm x 5 cm) was 
used with the following gradient: 0O/o-50% B for 30 min; 500/0-100% 
for 60 min; 1000/0 B for 10min. Buffer A is 0.060/o TFA in H20, and 
buffer B is 0.052% TFA in 800/o acetonitrile. The flow rate was 1 ml/min 
and UV absorbance was monitored at 214 and at 280 nm. Fractions 
were collected at 200-250 ~1 each and counted by LSC. Radioactive 
fractions were then submitted for sequencing by Edman degradation. 
Molecular model ing 
The structure of SHC was downloaded from Brookhaven Database 
(identification code 1SQC) into INSIGHT II (Biosym Technologies, 
version 97). The ligand (LDAO) used for crystallization was 
removed, but crystallographic water molecules were retained during 
modeling. Hydrogen atoms were added using the software programs 
provided, and then allowed to move for 1000 steps, followed by min- 
imization of the entire enzyme for 2000 steps using the method of 
steepest descents. 
The ligand was built by the Builder module, energy minimized (CVFF 
force field) to energy derivatives of less than 0.1 kcal/A, and manually 
docked into energy-minimized SHC, while monitoring the energy 
change using the Docking module. Energy minimization was first run 
for 2000 steps using steepest descents, !ollowed by minimizing to the 
energy derivatives of less than 0.1 kcal/A using the conjugate gradi- 
ents method. Molecular dynamics ran for 10,000 iterations of 1 fs 
after 1000 steps of equilibration, while the distance between BP 
oxygen and the CceH of Ala44 was constrained to be 3.0-3.5 A. All 
energy minimization and molecular dynamics, except calculation of 
ligand alone, were carried out at pH 6.0, temperature 333K, and cut- 
off distance of 15 A with switching-function width of 1.5 ,~,. This tem- 
perature was selected to reflect the 60°C optimal temperature for the 
enzymatic reaction. 
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